NEW INSULIN PEN IS FIRST WITH DIGITAL MEMORY; MAY HELP SIMPLIFY DIABETES MANAGEMENT

Another new pen with smaller-increment dosing available in April

Story Summary:

Diabetes management can be overwhelming, and data shows less than half of the 15 million being treated for diabetes have blood sugar levels within the recommended range. People with diabetes who use insulin must balance meals and exercise with carefully measured doses of insulin. This is not an easy task. But now, a new cutting-edge insulin pen, HumaPen® MEMOIR™, has been launched that may help simplify the management of diabetes, and a second new insulin pen, HumaPenŽ LUXURA™ HD, will be launched in April. Both MEMOIR and LUXURA HD are for use with Humalog®, (insulin lispro injection [rDNA origin]) the most-prescribed mealtime insulin in the US. MEMOIR is the first insulin pen with memory (it tracks the date, time and amount of the past 16 insulin doses, including priming doses), which can be important for patients and doctors in developing a treatment plan. LUXURA HD will be able to deliver insulin in half-unit increments, after the first unit, and may be attractive to parents of some children with diabetes. Both pens also resemble writing pens for less noticeable injections in public.

Additionally, Eli Lilly and Company, makers of MEMOIR and LUXURA HD, sponsored a national survey of people with diabetes. Not surprisingly, two-thirds said a reusable pen that tracks the date, time and amount of insulin would find it valuable. For more information, visit: www.humalog.com.

Soundbites

• Dr. Timothy Wahl, endocrinologist
• Dr. Linda Siminerio, University of Pittsburgh Diabetes Institute; International Diabetes Federation
• Reuben Bresler, type 1 diabetes patient
• Matt Beebe, Humalog brand leader, Lilly

B-Roll Includes

**patient lifestyle footage
**Dr/Patient exam
**footage of pen

VIDEO PROVIDED BY: "Eli Lilly and Company"

Indication

Humalog is for use in patients with diabetes to control high blood sugar and should be used with a longer-acting insulin, except when used in combination with sulfonylureas in patients with type 2 diabetes.

Important safety information for Humalog

Humalog is contraindicated during episodes of hypoglycemia and in patients sensitive to Humalog or one of its excipients. Safety and effectiveness in patients less than three years of age have not been established. There are no clinical studies of the use of Humalog in pregnancy or nursing mothers. Potential side effects associated with the use of all insulins include low blood sugar, weight gain, low blood potassium, changes in fat tissue at the site of injection, and allergic reactions, both general and local. Starting or changing insulin therapy should be done cautiously and only under medical supervision.

Humalog starts working quickly because it is absorbed quickly. That's why you should use it at mealtime and take it within 15 minutes before or immediately after your meal. Because Humalog is a mealtime insulin, you may also need a longer-acting insulin to get the best blood sugar control (except when using an insulin pump).

For complete user instructions for HumaPen MEMOIR, please refer to the full user manual provided with the pen. Humalog, HumaPen MEMOIR and HumaPen LUXURA HD require a prescription.

For additional important safety information, visit www.humalog.com

Humalog® is a registered trademark of Eli Lilly and Company. HumaPen® MEMOIR™ and HumaPen® LUXURA™ HD are trademarks of Eli Lilly and Company.